{"success":true,"data":{"pressRelease":{"id":"154596","rtpr_id":"nGNX7N4XrR-20260928","ticker":"ENOV","exchange":"NYSE","all_tickers":["ENOV","TFX","NYXH"],"title":"Nyxoah Appoints Liam Kelly as Chief Executive Officer","author":"Globe Newswire","published_at":"2026-09-28T20:30:00.633Z","article_body":"REGULATED INFORMATION\nINSIDE INFORMATION\n\nNyxoah Appoints Liam Kelly as Chief Executive Officer\n\nFurther strengthening the Company’s strategic U.S. presence and focus\n\nMont-Saint-Guibert, Belgium – September 28, 2026, 10:30 pm CET / 4:30 pm ET\n– Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the\n“Company”), a medical technology company that develops breakthrough\ntreatment alternatives for Obstructive Sleep Apnea (OSA) through\nneuromodulation, today announced the appointment of Liam Kelly as Chief\nExecutive Officer, effective October 1, 2026, succeeding Olivier Taelman.\n\nThe appointment reflects Nyxoah’s continued evolution into a U.S.-focused\ncommercial organization following FDA approval and the launch of Genio in the\nUnited States.\n\nLiam Kelly brings more than 25 years of leadership experience. He served as\nChairman, President and Chief Executive Officer of Teleflex Incorporated\n(NYSE: TFX), a global provider of medical technology products, until January\n2026. He led Teleflex as President and Chief Executive Officer from January\n2018 and as Chairman of the Board from May 2020. Mr. Kelly joined Teleflex in\n2009 and held a series of senior operating roles, including President of EMEA,\nPresident, International, President, Americas, and Chief Operating Officer.\nBefore Teleflex, he spent ten years at Hill-Rom Holdings, Inc. in senior\nmanagement roles. Mr. Kelly is a director of Enovis Corporation (NYSE: ENOV)\nand holds a Bachelor of Business Studies from the University of Limerick.\n\n“Nyxoah is entering a new chapter, with the United States at the center of\nour growth strategy. We are very pleased to welcome Liam as our new CEO. He is\na seasoned U.S. MedTech executive with a strong track record of scaling\norganizations, driving commercial performance and creating shareholder\nvalue,” said Robert Taub, Chairman of Nyxoah. “On behalf of the Board, I\nalso want to thank Olivier for his leadership over the past seven years and\nhis contribution in bringing Nyxoah from clinical development through FDA\napproval and into U.S. commercialization.”\n\n“I am incredibly excited to join Nyxoah at this pivotal stage,” said Liam\nKelly. “Genio is a truly differentiated technology in the treatment of sleep\napnea. The technology has tremendous potential to impact patient lives\nglobally. The U.S. launch is still in its early stages, and the momentum\nwe’re seeing in physician adoption gives me great confidence in what lies\nahead. Drawing on my experience at Teleflex building and scaling global\nbusinesses, I look forward to working with the Nyxoah team to scale the\nbusiness and bring Genio to many more OSA patients.”\n\nAbout Nyxoah\n\nNyxoah is a medical technology company focused on the development and\ncommercialization of innovative solutions to treat OSA. Nyxoah’s lead\nsolution is the Genio system, a patient-centered, leadless and battery-free\nhypoglossal neurostimulation therapy for OSA, the world’s most common sleep\ndisordered breathing condition that is associated with increased mortality\nrisk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA\npatients should enjoy restful nights and feel enabled to live their life to\nits fullest.\n\nFollowing the successful completion of the BLAST OSA study, the Genio system\nreceived its European CE Mark in 2019. Nyxoah completed two successful IPOs:\non Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the\npositive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval\nfor the expansion of its therapeutic indications to Complete Concentric\nCollapse (CCC) patients, currently contraindicated in competitors’ therapy.\nAdditionally, the Company announced positive outcomes from the DREAM IDE\npivotal study in 2024 and received approval from the FDA in August 2025, with\nthe treatment of CCC patients included in the warning section of our\nindications for use.\n\nFor more information, please visit http://www.nyxoah.com.\n\nCaution – CE marked since 2019. FDA approved in August 2025 as\nprescription-only device.\n\nForward-looking statements\n\nCertain statements, beliefs and opinions in this press release are\nforward-looking, which reflect the Company’s or, as appropriate, the Company\ndirectors’ or management’s current expectations regarding the appointment\nof the Chief Executive Officer and the related leadership transition; the\nCompany’s leadership and organizational structure; the Company’s\ncommercialization strategy in the U.S. market; the Company’s results of\noperations, financial condition, liquidity, performance, prospects, growth,\nfuture revenue and strategies. By their nature, forward-looking statements\ninvolve a number of risks, uncertainties, assumptions and other factors that\ncould cause actual results or events to differ materially from those expressed\nor implied by the forward-looking statements. These risks, uncertainties,\nassumptions and factors could adversely affect the outcome and financial\neffects of the plans and events described herein. These risks and\nuncertainties include, but are not limited to, the risks and uncertainties set\nforth in the “Risk Factors” section of the Company’s Annual Report on\nForm 20-F for the year ended December 31, 2025, filed with the Securities and\nExchange Commission (“SEC”) on March 26, 2026 and subsequent reports that\nthe Company files with the SEC. A multitude of factors including, but not\nlimited to, changes in demand, competition and technology, can cause actual\nevents, performance or results to differ significantly from any anticipated\ndevelopment. Forward-looking statements contained in this press release\nregarding past trends or activities are not guarantees of future performance\nand should not be taken as a representation that such trends or activities\nwill continue in the future. In addition, even if actual results or\ndevelopments are consistent with the forward-looking statements contained in\nthis press release, those results or developments may not be indicative of\nresults or developments in future periods. No representations and warranties\nare made as to the accuracy or fairness of such forward-looking statements. As\na result, the Company expressly disclaims any obligation or undertaking to\nrelease any updates or revisions to any forward-looking statements in this\npress release as a result of any change in expectations or any change in\nevents, conditions, assumptions or circumstances on which these\nforward-looking statements are based, except if specifically required to do so\nby law or regulation. Neither the Company nor its advisers or representatives\nnor any of its subsidiary undertakings or any such person’s officers or\nemployees guarantees that the assumptions underlying such forward-looking\nstatements are free from errors nor does either accept any responsibility for\nthe future accuracy of the forward-looking statements contained in this press\nrelease or the actual occurrence of the forecasted developments. You should\nnot place undue reliance on forward-looking statements, which speak only as of\nthe date of this press release.\n\nContacts:\n\nNyxoah\n\nRémi Renard, Head of Investor Relations & Corporate Communication\nIR@nyxoah.com\n\nAttachment\n*     ENGLISH_Nyxoah Appoints Liam Kelly as CEO_FINAL\n(https://ml-eu.globenewswire.com/Resource/Download/5dd59a0b-db7d-4fd5-bba9-780cc1ff7cfa)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a71f8653-a2aa-46a0-ad48-7eb6b9091673)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7N4XrR-20260928","title":"Nyxoah Appoints Liam Kelly as Chief Executive Officer","author":"Globe Newswire","ticker":"ENOV","created":"2026-09-28T20:30:00.633Z","tickers":["ENOV","TFX","NYXH"],"exchange":"NYSE","article_body":"REGULATED INFORMATION\nINSIDE INFORMATION\n\nNyxoah Appoints Liam Kelly as Chief Executive Officer\n\nFurther strengthening the Company’s strategic U.S. presence and focus\n\nMont-Saint-Guibert, Belgium – September 28, 2026, 10:30 pm CET / 4:30 pm ET\n– Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the\n“Company”), a medical technology company that develops breakthrough\ntreatment alternatives for Obstructive Sleep Apnea (OSA) through\nneuromodulation, today announced the appointment of Liam Kelly as Chief\nExecutive Officer, effective October 1, 2026, succeeding Olivier Taelman.\n\nThe appointment reflects Nyxoah’s continued evolution into a U.S.-focused\ncommercial organization following FDA approval and the launch of Genio in the\nUnited States.\n\nLiam Kelly brings more than 25 years of leadership experience. He served as\nChairman, President and Chief Executive Officer of Teleflex Incorporated\n(NYSE: TFX), a global provider of medical technology products, until January\n2026. He led Teleflex as President and Chief Executive Officer from January\n2018 and as Chairman of the Board from May 2020. Mr. Kelly joined Teleflex in\n2009 and held a series of senior operating roles, including President of EMEA,\nPresident, International, President, Americas, and Chief Operating Officer.\nBefore Teleflex, he spent ten years at Hill-Rom Holdings, Inc. in senior\nmanagement roles. Mr. Kelly is a director of Enovis Corporation (NYSE: ENOV)\nand holds a Bachelor of Business Studies from the University of Limerick.\n\n“Nyxoah is entering a new chapter, with the United States at the center of\nour growth strategy. We are very pleased to welcome Liam as our new CEO. He is\na seasoned U.S. MedTech executive with a strong track record of scaling\norganizations, driving commercial performance and creating shareholder\nvalue,” said Robert Taub, Chairman of Nyxoah. “On behalf of the Board, I\nalso want to thank Olivier for his leadership over the past seven years and\nhis contribution in bringing Nyxoah from clinical development through FDA\napproval and into U.S. commercialization.”\n\n“I am incredibly excited to join Nyxoah at this pivotal stage,” said Liam\nKelly. “Genio is a truly differentiated technology in the treatment of sleep\napnea. The technology has tremendous potential to impact patient lives\nglobally. The U.S. launch is still in its early stages, and the momentum\nwe’re seeing in physician adoption gives me great confidence in what lies\nahead. Drawing on my experience at Teleflex building and scaling global\nbusinesses, I look forward to working with the Nyxoah team to scale the\nbusiness and bring Genio to many more OSA patients.”\n\nAbout Nyxoah\n\nNyxoah is a medical technology company focused on the development and\ncommercialization of innovative solutions to treat OSA. Nyxoah’s lead\nsolution is the Genio system, a patient-centered, leadless and battery-free\nhypoglossal neurostimulation therapy for OSA, the world’s most common sleep\ndisordered breathing condition that is associated with increased mortality\nrisk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA\npatients should enjoy restful nights and feel enabled to live their life to\nits fullest.\n\nFollowing the successful completion of the BLAST OSA study, the Genio system\nreceived its European CE Mark in 2019. Nyxoah completed two successful IPOs:\non Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the\npositive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval\nfor the expansion of its therapeutic indications to Complete Concentric\nCollapse (CCC) patients, currently contraindicated in competitors’ therapy.\nAdditionally, the Company announced positive outcomes from the DREAM IDE\npivotal study in 2024 and received approval from the FDA in August 2025, with\nthe treatment of CCC patients included in the warning section of our\nindications for use.\n\nFor more information, please visit http://www.nyxoah.com.\n\nCaution – CE marked since 2019. FDA approved in August 2025 as\nprescription-only device.\n\nForward-looking statements\n\nCertain statements, beliefs and opinions in this press release are\nforward-looking, which reflect the Company’s or, as appropriate, the Company\ndirectors’ or management’s current expectations regarding the appointment\nof the Chief Executive Officer and the related leadership transition; the\nCompany’s leadership and organizational structure; the Company’s\ncommercialization strategy in the U.S. market; the Company’s results of\noperations, financial condition, liquidity, performance, prospects, growth,\nfuture revenue and strategies. By their nature, forward-looking statements\ninvolve a number of risks, uncertainties, assumptions and other factors that\ncould cause actual results or events to differ materially from those expressed\nor implied by the forward-looking statements. These risks, uncertainties,\nassumptions and factors could adversely affect the outcome and financial\neffects of the plans and events described herein. These risks and\nuncertainties include, but are not limited to, the risks and uncertainties set\nforth in the “Risk Factors” section of the Company’s Annual Report on\nForm 20-F for the year ended December 31, 2025, filed with the Securities and\nExchange Commission (“SEC”) on March 26, 2026 and subsequent reports that\nthe Company files with the SEC. A multitude of factors including, but not\nlimited to, changes in demand, competition and technology, can cause actual\nevents, performance or results to differ significantly from any anticipated\ndevelopment. Forward-looking statements contained in this press release\nregarding past trends or activities are not guarantees of future performance\nand should not be taken as a representation that such trends or activities\nwill continue in the future. In addition, even if actual results or\ndevelopments are consistent with the forward-looking statements contained in\nthis press release, those results or developments may not be indicative of\nresults or developments in future periods. No representations and warranties\nare made as to the accuracy or fairness of such forward-looking statements. As\na result, the Company expressly disclaims any obligation or undertaking to\nrelease any updates or revisions to any forward-looking statements in this\npress release as a result of any change in expectations or any change in\nevents, conditions, assumptions or circumstances on which these\nforward-looking statements are based, except if specifically required to do so\nby law or regulation. Neither the Company nor its advisers or representatives\nnor any of its subsidiary undertakings or any such person’s officers or\nemployees guarantees that the assumptions underlying such forward-looking\nstatements are free from errors nor does either accept any responsibility for\nthe future accuracy of the forward-looking statements contained in this press\nrelease or the actual occurrence of the forecasted developments. You should\nnot place undue reliance on forward-looking statements, which speak only as of\nthe date of this press release.\n\nContacts:\n\nNyxoah\n\nRémi Renard, Head of Investor Relations & Corporate Communication\nIR@nyxoah.com\n\nAttachment\n*     ENGLISH_Nyxoah Appoints Liam Kelly as CEO_FINAL\n(https://ml-eu.globenewswire.com/Resource/Download/5dd59a0b-db7d-4fd5-bba9-780cc1ff7cfa)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a71f8653-a2aa-46a0-ad48-7eb6b9091673)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-28T20:30:00.668308821Z","server_sent_at_ms":1790627400668},"received_at":"2026-09-28T20:30:00.901Z","source_url":null},"analysis":{"id":"143351","press_release_id":"154596","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"executive_change","narrative":"Nyxoah SA (Nasdaq/Euronext: NYXH) appointed Liam Kelly as Chief Executive Officer effective October 1, 2026, succeeding Olivier Taelman after seven years at the helm.\n\nKelly was Chairman, President and CEO of Teleflex until January 2026 and currently serves on the board of Enovis Corporation (NYSE: ENOV), bringing more than 25 years of MedTech leadership experience.\n\nThe move underscores Nyxoah's shift to a US-focused commercial organization following August 2025 FDA approval and the early-stage launch of its Genio neuromodulation therapy for obstructive sleep apnea.\n\nFor Enovis, the news is contextual: its director takes a full-time CEO role elsewhere, which investors may monitor for board-commitment implications.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Ex-Teleflex CEO Liam Kelly takes the Nyxoah helm to scale the early US Genio launch; ENOV director slot in focus."},"keyFigures":{},"quotedText":"He is a seasoned U.S. MedTech executive with a strong track record of scaling organizations, driving commercial performance and creating shareholder value","namedEntities":{"people":[{"name":"Liam Kelly","role":"incoming CEO"},{"name":"Olivier Taelman","role":"outgoing CEO"},{"name":"Robert Taub","role":"Chairman"},{"name":"Rémi Renard","role":"Head of Investor Relations & Corporate Communication"}],"products":["Genio"],"companies":[{"name":"Nyxoah SA","ticker":"NYXH"},{"name":"Teleflex Incorporated","ticker":"TFX","relationship":"Kelly's prior employer"},{"name":"Enovis Corporation","ticker":"ENOV","relationship":"Kelly serves as director"},{"name":"Hill-Rom Holdings, Inc.","relationship":"Kelly's prior employer"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"CEO transition, but this is a planned appointment of a seasoned US MedTech executive (ex-Teleflex CEO Liam Kelly) to lead the US commercialization push, not an abrupt departure. Successor named and effective date given."},"tickerRelevance":{"others":[{"ticker":"NYXH","relevance":"primary issuer of the press release; ENOV director appointed its CEO"},{"ticker":"TFX","relevance":"mentioned - incoming CEO's former company"}],"primary":"ENOV"},"globalImportance":35,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"enovAngle":"director departs to CEO role at Nyxoah","tickerTier":"small-cap","eventGravity":"planned CEO succession with named successor","sectorWeight":"medtech"}},"event_type":"executive_change","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Nyxoah SA (Nasdaq/Euronext: NYXH) appointed Liam Kelly as Chief Executive Officer effective October 1, 2026, succeeding Olivier Taelman after seven years at the helm.\n\nKelly was Chairman, President and CEO of Teleflex until January 2026 and currently serves on the board of Enovis Corporation (NYSE: ENOV), bringing more than 25 years of MedTech leadership experience.\n\nThe move underscores Nyxoah's shift to a US-focused commercial organization following August 2025 FDA approval and the early-stage launch of its Genio neuromodulation therapy for obstructive sleep apnea.\n\nFor Enovis, the news is contextual: its director takes a full-time CEO role elsewhere, which investors may monitor for board-commitment implications.","key_figures":{},"named_entities":{"people":[{"name":"Liam Kelly","role":"incoming CEO"},{"name":"Olivier Taelman","role":"outgoing CEO"},{"name":"Robert Taub","role":"Chairman"},{"name":"Rémi Renard","role":"Head of Investor Relations & Corporate Communication"}],"products":["Genio"],"companies":[{"name":"Nyxoah SA","ticker":"NYXH"},{"name":"Teleflex Incorporated","ticker":"TFX","relationship":"Kelly's prior employer"},{"name":"Enovis Corporation","ticker":"ENOV","relationship":"Kelly serves as director"},{"name":"Hill-Rom Holdings, Inc.","relationship":"Kelly's prior employer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-28T20:30:06.766Z","global_importance":35,"audience_relevance":25,"importance_components":{"enovAngle":"director departs to CEO role at Nyxoah","tickerTier":"small-cap","eventGravity":"planned CEO succession with named successor","sectorWeight":"medtech"}},"durationMs":5441,"modelName":"glm-5.3-flashx"}}